Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Botox and PRP: a surprising new hope for hair loss?

NCT ID NCT07335367

Disease control Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 10, 2026 · Updated 2 times

Summary

This study is testing whether combining platelet-rich plasma (PRP) with Botox injections works better than PRP alone for treating androgenetic alopecia (common pattern baldness). About 76 adults aged 18 to 60 with mild to moderate hair loss will receive either the combo treatment or PRP only, once a month for three months. Researchers will track changes in hair density and safety over six months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

83 people

The number who actually took part.

Started

Jan 2026

Finished

Aug 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who meet the diagnostic criteria for AGA, confirmed by medical history, clinical presentation, and trichoscopy, with a stage of Norwood-Hamilton III to V or Ludwig I to III. 2. Patients provide informed consent and voluntarily participate in the study. 3. A signed informed consent form is obtained. 4. Age between 18 and 60 years, in good general health. 5. No use of any medications for AGA treatment within the past 6 months. 6. Absence of alopecia areata, local infection, or neuromuscular diseases. Exclusion Criteria: 1. Disease duration exceeding 5 years. 2. Patients who do not meet the diagnostic criteria for AGA. 3. Individuals with coagulation disorders. 4. Patients with active skin diseases or other severe systemic illnesses. 5. Patients with blood-borne infectious diseases such as Hepatitis A, Hepatitis B, HIV/AIDS, or Syphilis. 6. Use of any medications for hair loss treatment within the past 6 months. 7. Other conditions deemed by the investigator as unsuitable for participation, including but not limited to unreliable patients, or those unable to undergo or comprehend the study assessments.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Androgenetic alopecia (AGA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

alopecia androgenetic alopecia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Androgenetic alopecia (AGA)

Contacts and locations

Locations

  • Nanfang Hospital Southern Medical University

    Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.